Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Immune Response Corp (IMNR) since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data at Immune Response Corp. Table 2 shows the detailed insider transactions. The reporting company's CIK number is 817785.
Total stock buying since 2005: $98,880.
Total stock sales since 2005: $21,936,244.
Total stock option exercises since 2005: $0.
▪ Recent SEC 13D filings for all companies
▪ Recent portfolio reports of all companies
Insider Buying | Insider Sales | Option Exercises | ||||
---|---|---|---|---|---|---|
Year | Shares | Value | Shares | Value | Shares | Value |
2006 | 3,600,000 | $79,400 | 11,250,000 | $21,936,244 | 0 | $0 |
2005 | 9,683,060 | $19,480 | 0 | $0 | 0 | $0 |
Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
---|---|---|---|---|---|---|
year-month | Shares | Value | Shares | Value | Shares | Value |
2006-11 | 0 | $0 | 7,145,000 | $13,729,794 | 0 | $0 |
2006-10 | 0 | $0 | 1,075,000 | $2,146,450 | 0 | $0 |
2006-09 | 0 | $0 | 2,330,000 | $4,660,000 | 0 | $0 |
2006-08 | 500,000 | $9,000 | 700,000 | $1,400,000 | 0 | $0 |
2006-07 | 2,900,000 | $66,400 | 0 | $0 | 0 | $0 |
2006-06 | 200,000 | $4,000 | 0 | $0 | 0 | $0 |
2005-09 | 9,683,060 | $19,480 | 0 | $0 | 0 | $0 |
Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2006-11-09 | Green Michael K (COO and CFO) | Sale | 2,474,900 | 1.92 | 4,751,808 |
2006-11-08 | Green Michael K (COO and CFO) | Sale | 1,770,000 | 1.90 | 3,363,000 |
2006-11-07 | Green Michael K (COO and CFO) | Sale | 325,600 | 1.91 | 621,896 |
2006-11-06 | Green Michael K (COO and CFO) | Sale | 158,000 | 1.91 | 301,780 |
2006-11-03 | Green Michael K (COO and CFO) | Sale | 1,042,500 | 1.92 | 2,001,600 |
2006-11-02 | Green Michael K (COO and CFO) | Sale | 1,041,000 | 1.96 | 2,040,360 |
2006-11-01 | Green Michael K (COO and CFO) | Sale | 333,000 | 1.95 | 649,350 |
2006-10-31 | Green Michael K (COO and CFO) | Sale | 355,000 | 1.99 | 706,450 |
2006-10-19 | Theofan Georgia (VP, Clinical Development) | Sale | 720,000 | 2.00 | 1,440,000 |
2006-09-15 | Theofan Georgia (VP, Clinical Development) | Sale | 150,000 | 2.00 | 300,000 |
2006-09-08 | Theofan Georgia (VP, Clinical Development) | Sale | 2,180,000 | 2.00 | 4,360,000 |
2006-08-31 | Theofan Georgia (VP, Clinical Development) | Sale | 200,000 | 2.00 | 400,000 |
2006-08-29 | Theofan Georgia (VP, Clinical Development) | Sale | 250,000 | 2.00 | 500,000 |
2006-08-25 | Theofan Georgia (VP, Clinical Development) | Sale | 250,000 | 2.00 | 500,000 |
2006-08-21 | Hochman David P (Director) | Buy | 500,000 | .02 | 9,000 |
2006-07-28 | Hochman David P (Director) | Buy | 2,600,000 | .02 | 59,800 |
2006-07-27 | Hochman David P (Director) | Buy | 300,000 | .02 | 6,600 |
2006-06-19 | Hochman David P (Director) | Buy | 200,000 | .02 | 4,000 |
2005-09-22 | Kimberlin Kevin (10% Owner) | Buy | 9,643,060 | .00 | 0 |
2005-09-06 | Green Michael K (VP, Finance and CFO) | Buy | 30,000 | .50 | 14,880 |
2005-09-02 | Bonfiglio John N (CEO) | Buy | 10,000 | .46 | 4,600 |
Insider trading activities including stock purchases, stock sales, and option exercises of IMNR listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Immune Response Corp (symbol IMNR, CIK number 817785) see the Securities and Exchange Commission (SEC) website.